Form D · Biotechnology
Cantai Therapeutics, Inc.
Philadelpia, PA · CIK 0001991732
Offering snapshot reported Jan 21, 2026 · SEC filing
- Reported sold
- $3M Offering amount: $3M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Jan 15, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 21, 2026 | Initial | $3,000,000 | No comparison | 3 | SEC filing |
| Jul 15, 2025 | Initial | $550,000 | No comparison | 3 | SEC filing |
| Nov 20, 2023 | Initial | $700,000 | No comparison | 3 | SEC filing |
| Nov 20, 2023 | Amendment | $700,000 | $0vs Nov 20, 2023 | 3 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-570571
Source: Form D, filed Jan 21, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Errik B. Anderson | Executive |
| Joshua Brandt | Director |
| Ross Leimberg | Director, Executive |
| Geeta Vemuri | Director, Executive |
| Getta Vemuri | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3675 Market Street Suite 200
Philadelpia, PA, 19104
Philadelpia, PA, 19104